Corona Remedies Q2 FY27 Earnings Call: Reaffirms 15% Revenue Growth Guidance, Chronic Portfolio Grows 29%

Corona Remedies Ltd held its Q2 FY27 earnings call on October 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Steady Quarter: 22% Growth, Flat Margins, Moderate PAT

• Q2 FY27 revenue of Rs.441 Cr — versus Rs.361 Cr in Q2 FY26, a 22.2% YoY increase; H1 FY27 revenue also grew 22% YoY, or ~21-21.5% in Q2 and 21.5% in H1 excluding the acquired Vokadin brand.
• Q2 EBITDA of Rs.96 Cr — up 22.3% YoY from Rs.78.5 Cr, with margin stable at 20.7%; H1 FY27 EBITDA grew 27.5% with margin at 31.9% as stated by the CFO.
• Q2 PAT of Rs.60 Cr (+15.3% YoY) — PAT margin of 13.7%; the CFO attributed the moderate PAT growth versus revenue to higher depreciation and amortization from newly commissioned facilities and brand acquisitions.
• H1 FY27 PAT of Rs.120 Cr (+22.2% YoY) — PAT margin of 13.9%; H1 return metrics were ROCE of 49.8% and ROE of 32.9%.
• India contributed 97% of revenue — in both Q2 FY27 and H1 FY27, underscoring the domestic concentration of the business.

Consistent Outperformance Against the IPM

• India business grew 22.9% YoY in Q2 FY27 — significantly ahead of the IPM's ~12% growth in the same period as per PharmaTrac; H1 FY27 India growth was 22.8%.
• Chronic portfolio grew ~29% in Q2 FY27 — nearly 2x the corresponding chronic IPM segment's 14.9% growth, which management said reinforces confidence in business fundamentals.
• 3-year track record of 1.9x the IPM — per PharmaTrac, driven by volume growth of 3.3x the market, new introduction growth of 2.2x, and price growth of 1.2x.
• Ranked 14th among top-15 covered-market companies — and 26th overall in the IPM, remaining one of the fastest-growing companies in the market.
• IPM context per PharmaTrac — the market has delivered low-to-mid double-digit growth since December 2025, with its highest-ever monthly growth of 13.5% in September 2025; management views Indian pharma as a sunrise sector.
• Price growth has stepped up — analyst Siddharth Gandhi (CWC) cited 8.74% in Q1 FY27 and 8.9% in Q2 FY27 versus ~5% historically (FY23-FY26); management confirmed historical ~5-5.5% and expects the elevated run-rate to "more or less continue" as the third growth pillar.

Margin Trajectory and the MR Investment

• FY26 EBITDA margin was 20.9% — the CFO cited the 400+ medical reps added in Q2 FY27 as a near-term EBITDA impact, and said operating margins will improve over coming years (FY 2027-2028 onward).
• No mid-20s margin guidance — the CFO explicitly clarified that a mid-20s EBITDA margin was never guided by the company, and it has never issued guidance on operating margin.
• Field force at 3,111 MRs — after ~400 MRs were added in Q4 FY26; no additions are planned for now, with a potential addition of ~150 MRs anytime in FY28 (not yet decided).
• Execution risk on Vokardine — integration and business-model change are progressing slower than expected; the next two quarters (Q3-Q4 FY27) are expected to provide more visibility.
• Vokardine 25% CAGR confidence — management remains confident of a 25% CAGR for Vokardine over 3 to 4 years (through FY 2029-2030/FY 2030-2031) after commercializing it in FY 2026-2027 and completing distribution/supply chain integration.

Infertility Launch, Therapy Cadence and Inorganic Pipeline

• IVF task force of 46 MRs at ~Rs.7 lakh PCPM — within its first six months (as of Q2 FY27); management expects Rs.8-9 lakh PCPM by end of FY 2026-2027, covering ~2,500 infertility professionals (~75-80% of the addressable market in present territories).
• No IVF field force expansion in year one — any expansion would be considered only in H2 CY27 or early CY28, not before.
• Five new therapy areas targeted via M&A — nephrology, neuropsychiatry, gastroenterology, spine, and rheumatology, via brand or small-company acquisitions, with deals actively being worked on; management said the current portfolio has "hardly a gap."
• Infertility focus began in CY 2026 — with a dedicated task force set up in FY 2026-2027 and efforts spanning roughly the past two quarters (H1 FY27); management said it will "definitely try" to begin additional new therapies in a coming quarter or the coming year (into FY 2027-2028).
• Valuation anchored to own business plan — management does not anchor on market multiples, deciding the multiple based on its plan for building an acquired brand over the next 3-5 years (from Q2 FY27).
• MNC pipeline limited — Corona is working with an MNC on a proposal, but not in the five new therapies; management stated there is nothing on the desk from MNCs for those areas.

Soft H1 Exports, Hormone-Led Build-Out, Semaglutide Context

• Exports of Rs.12.6 Cr in Q2 FY27 — and Rs.25.3 Cr in H1 FY27; H1 international growth was soft, attributed to the B2B model and differing country registration guidelines ("normal course").
• FY27 international guidance of Rs.60-65 Cr — based on the order book, with ~15% international revenue growth expected by end of FY 2026-2027 and ~15% export growth expected in FY 2027-2028.
• 10-12 hormone dossiers in advanced preparation — for Europe, Brazil, Mexico, CIS, Russia, LATAM and Asia; partner-led registration takes 1-2 years with commercial results expected in 2-3 years, and international is expected to remain below 10% of total revenue even after that, with India staying the core focus.
• Backward integration via La Chandra stake — a hormonal API player with ROFO rights and certain conditions attached; forward integration via a newly built plant in Ahmedabad, currently at the dossier stage with no timeline disclosed for going "all out" in world markets.
• Semaglutide market sizing divergence — management expects a Rs.1,200-1,400 Cr semaglutide market in the first year post-launch (≈FY 2026-2027), versus the Rs.3,000-5,000 Cr first-year market size being talked about by market participants; Corona is already among the top 10 players in the market.

Guidance Reaffirmed; NLEM Exposure Limited

• FY27 revenue growth guidance reaffirmed at 1.5x IPM — ≈15%, assuming ~10% IPM growth; the CEO agreed stronger IPM growth could imply upside to the 15% figure but confirmed 1.5x remains the guidance.
• Standing guidance of 15% revenue growth and 20% PAT growth — reiterated by the CFO (period unspecified).
• IPM outlook of 10-12% over the next three-four quarters — Q3 FY 2026-2027 through ~Q2 FY 2027-2028; the CEO's ~10%+ expectation was explicitly framed as his "individual gut feel," with LOE momentum and awareness cited as possible but unconfirmed drivers ("nobody knows the reason").
• No change in competitive intensity observed — from smaller branded-generic players or alternate channels (trade generics, Jan Aushadhi, private label generics) over the last 3-4 quarters, with rising patient footfalls at clinics and corporate hospitals and the cause unclear.
• NLEM exposure declining — NLEM portfolio contribution fell from ~9% to 7.5% (as of Q2 FY27); 0% of top five brand SKUs are under NLEM, with only a few Cort brand SKUs affected at ~7-8%; management sees limited NLEM risk since cardio-diabetes products are already on the list.
• Trade margin cap not impacting Corona — management stated the cap applies to the trade channel (hospitals/pharmacies), not the pharmaceutical industry, and that the government has applied it on the majority of onco products; Corona is not being impacted as of Q2 FY27.